Clinical trials: Digestive Disease
Hepatitis C, Chronic, HIV Infection
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
The main objective is to evaluate the hepatic safety of raltegravir when compared to efavirenz, both in combination with tenofovir and emtricitabine as first-line HIV treatment in patients with HIV and hepatitis C coinfection.
- Trial name
- NCT01147107
- Testing
- Raltegravir, Efavirenz
- Where
- 2 sites in Vietnam
- Volunteers
- 80 people
- Sponsor
- University of Hawaii
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
The purpose of this study is to evaluate the safety and antiviral effect of multiple doses of ABT-493 and ABT-530 in adults with genotype 1 HCV.
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis
- Trial name
- NCT01995071
- Testing
- ABT-493, ABT-530, ABT-450/r/ABT-267, ABT-333
- Volunteers
- 89 people
- Sponsor
- AbbVie
Wound Care, Pain Intensity
Pain Medicine for Wound Care Procedures
This is a randomized double-blind study to determine if the administration of a small-dose of ketamine (an anesthetic)added to morphine (an opioid) contributes to reducing pain intensity during open wound care procedure (WCP)in…
- Conditions
- Wound Care, Pain Intensity, Hyperalgesia, Nausea
- Trial name
- NCT00701909
- Testing
- Morphine plus Ketamine
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV).
- Trial name
- NCT00436163
- Testing
- Peginterferon alfa-2a
- Where
- 9 sites in Estonia, Latvia and 1 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability…
- Trial name
- NCT04412863
- Testing
- VIR-2218, pegylated interferon-alfa 2a
- Where
- 22 sites in Australia, Hong Kong and 4 more
- Volunteers
- 84 people
- Sponsor
- Vir Biotechnology, Inc.
Refractory Metastatic Colorectal Cancer
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus…
- Trial name
- SUNLIGHT (NCT04737187)
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- 99 sites in United States, Austria and 12 more
- Volunteers
- 492 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Crohn Disease
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
The purpose of this study is to evaluate the efficacy of a treat to target strategy coupled with early endoscopic assessment versus a clinically driven (routine care) approach in achieving endoscopic response.
- Trial name
- STARDUST (NCT03107793)
- Testing
- Ustekinumab
- Where
- 107 sites in Belgium, Czechia and 10 more
- Volunteers
- 500 people
- Sponsor
- Janssen-Cilag Ltd.
C. Difficile, Diarrhea
Impact of Oral Antibiotic Treatment on C. Difficile
The overall aim is to characterize and to compare the extent and quantity of C. difficile stool shedding, perianal colonization and environmental contamination in patients who received oral fidaxomicin, oral metronidazole, or…
- Conditions
- C. Difficile, Diarrhea, Enterocolitis
- Trial name
- C-Diff (NCT02057198)
- Testing
- Fidaxomicin, Metronidazole, Vancomycin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Duke University
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis
- Trial name
- REMission (NCT00727298)
- Testing
- Infliximab
- Volunteers
- 4,485 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastro-oesophageal Reflux
Influence of IPV on GOR in Infants From 0 to 12 Months.
The purpose of this study is to determine whether Intrapulmonary Percussive Ventilation ( airway clearance technique) provokes or aggravates gastro-oesophageal reflux in infants from 0 to 12 months.
- Trial name
- NCT02124863
- Testing
- Intrapulmonary Percussive Ventilation
- Where
- Belgium
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Vrije Universiteit Brussel
Ulcerative Colitis
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
- Trial name
- NCT03760003
- Testing
- ABX464 100 mg, ABX464 50 mg, ABX464 25 mg
- Where
- 130 sites in United States, Austria and 15 more
- Volunteers
- 355 people
- Sponsor
- Abivax S.A.
Obscure Gastrointestinal Bleeding, Angiodysplasia
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Background: Repeated episodes of bleeding from gastrointestinal vascular malformations refractory to endoscopic or surgical therapy often pose a major therapeutic challenge.
- Conditions
- Obscure Gastrointestinal Bleeding, Angiodysplasia, Gastric Antral Vascular Ectasia, Thalidomide
- Trial name
- NCT00964496
- Testing
- Thalidomide, Iron
- Volunteers
- 55 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cystic Fibrosis
The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients
Insulin replacement therapy may be effective in breaking the cycle of protein catabolism, undernutrition and overall clinical deterioration in pre-diabetic, insulin insufficient CF youth because of its potent anabolic effect.
- Trial name
- NCT02496780
- Testing
- novolog insulin, levemir insulin
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Pancreatic Cancer
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
The primary goal of the research study is to determine whether treating pancreatic cancer patients with hydroxychloroquine in combination with gemcitabine before surgery is safe.
- Trial name
- NCT01128296
- Testing
- Hydroxychloroquine, Gemcitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Amer Zureikat
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy)…
- Trial name
- NCT00385203
- Testing
- AZD2171
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Chronic Hepatitis C
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or GT2 or GT3 chronic hepatitis C (CHC)…
- Trial name
- NCT02569710
- Testing
- AL-335, Odalasvir (ODV), Simeprevir (SMV)
- Where
- 11 sites in Mauritius, Moldova and 2 more
- Volunteers
- 161 people
- Sponsor
- Alios Biopharma Inc.
Cervical Cancer, HPV Cancers
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
Background: More than 30,000 cases of human papillomavirus (HPV) associated cancers occur annually in the United States. When these cancers spread, they do not respond well to standard treatments and are often incurable.
- Conditions
- Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04287868
- Testing
- PDS0101, M7824, NHS-IL12
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced…
- Trial name
- NCT04661150
- Testing
- Atezolizumab, Trastuzumab, Capecitabine
- Where
- 8 sites in China
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than…
- Trial name
- HEPCAT (NCT01125189)
- Testing
- Daclatasvir, peg-interferon alfa-2a, ribavirin
- Where
- 64 sites in United States, Australia and 9 more
- Volunteers
- 558 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.